Related Experiment Videos
Clinical applications of IL-2
1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Oncology (Williston Park, N.Y.)
|June 1, 1994
Summary
Interleukin-2 (IL-2) shows limited anticancer activity and significant toxicity in clinical trials, benefiting only a small subset of patients with metastatic renal cell carcinoma. Further research may optimize its use in immunotherapy for various diseases.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Preclinical studies suggested significant anticancer activity for Interleukin-2 (IL-2).
- Clinical trials revealed limited efficacy and substantial toxicity for IL-2 in cancer treatment.
- Current FDA-approved use in metastatic renal cell carcinoma benefits a small patient subset, with no identified prognostic factors.
Purpose of the Study:
- To evaluate the anticancer activity and toxicity of Interleukin-2 (IL-2) in clinical settings.
- To explore the potential of IL-2 in combination therapies and for other diseases.
Main Methods:
- Review of clinical trial data involving various doses, schedules, and combinations of IL-2.
- Analysis of patient responses and toxicities in metastatic renal cell carcinoma and melanoma.
- Assessment of IL-2's immunomodulatory effects.
Main Results:
- IL-2 demonstrated less anticancer activity than predicted from preclinical data.
- High-dose IL-2 for renal cell carcinoma resulted in significant acute toxicity.
- Durable complete responses were observed in a small percentage of patients with metastatic renal cell carcinoma and melanoma.
Conclusions:
- IL-2's clinical utility is limited by modest efficacy and significant toxicity.
- IL-2 may be valuable in immunotherapy, particularly in combination with other agents.
- IL-2 shows potential for treating infectious diseases and immunodeficiency states.